New abortive agents for the treatment of migraine

Advances in Internal Medicine

Volumn 46, Issue , 2001, Pages 1-29

  Potrebic, Sonja ^a   Raskin, Neil H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; NARATRIPTAN; OXAZOLIDINONE DERIVATIVE; PIPERIDINE DERIVATIVE; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; TRIAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE; ZOLMITRIPTAN;

CLINICAL TRIAL; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIGRAINE; PROGNOSIS; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; FEMALE; HUMANS; INDOLES; MALE; MIGRAINE DISORDERS; OXAZOLIDINONES; PIPERIDINES; PROGNOSIS; RECURRENCE; SEROTONIN AGONISTS; SEVERITY OF ILLNESS INDEX; SUMATRIPTAN; TREATMENT OUTCOME; TRIAZOLES; TRYPTAMINES;

EID: 0035218864     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (160)

1. Rasmussen BK, Jensen R, Schioll M et al: Epidemiology of headache in a general population-a prevalence study. J Clin Epidemiol 44:1147-1157, 1991.
2. Stewart WF, Lipton RB, Celentano DD, et al: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267:64-69, 1992.
3. Henry P, Michel P, Brochet B, et al: A nationwide survey of migraine in France: Prevalence and clinical features in adults. GRIM. Cephalalgia 12:229-237, 1992.
4. Breslau N, Davis GC: Migraine, physical health and psychiatric disorder: A prospective epidemiologic study in young adults. J Psychiatr Res 27:211-221, 1993.
5. Launer LJ, Terwindt GM, Ferrari MD: The prevalence and characteristics of migraine in a population-based cohort: The GEM study. Neurology 53:537-542, 1999.
6. Hu XH, Markson LE, Lipton RB, et al: Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 159:813-818, 1999.
7. Thorn TJ: Economic costs of neoplasms, arteriosclerosis, and diabetes in the United States. In Vivo 10:255-259,1996.
8. Weiss KB, Gergen PJ, Hodgson TA: An economic evaluation of asthma in the United States. NEnglJMed 326:862-866,1992.
9. Smith DH, Malone DC, Lawson KA, et al: A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 156:787-793, 1997.
10. Tfelt-Hansen P: Prophylactic phannacotherapy of migraine. Some practical guidelines. Neural Clin 15:153-165,1997.
11. Diener HG, Kaube H, Limmroth V: A practical guide to the management and prevention of migraine. Drugs 56:811-824,1998.
12. Zed PJ, Loewen PS, Robinson G: Medication-induced headache: Overview and systematic review of therapeutic approaches. Ann Pharmacother 33:61-72,1999.
13. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 8:1-93,1988.
14. Rasmussen BK, Jensen R, Olesen J: A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 11:129-134, 1991.
15. Leston JA: Migraine and tension-type headache are not separate disorders. Cephalalgia 16:220-222,1996.
16. Rasmussen BK: Migraine and tension-type headache are separate disorders. Cephalalgia 16:217-220; discussion 223, 1996.
17. Cady RK, Gutterman D, Saiers JA, et al: Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. Cephalalgia 17:588-590, 1997.
18. Mathew NT, Stubits E, Nigam MP: Transformation of episodic migraine into daily headache: Analysis of factors. Headache 22:66-68,1982.
19. Mathew NT, Reuveni U, Ferez F: Transformed or evolutive migraine. Headache 27:102-106,1987.
20. Mathew NT: Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin 15:167-186,1997.
21. Rapoport AM: Analgesic rebound headache. Headache 28:662-665, 1988.
22. Saper JR: Daily chronic headache. Neurol Clin 8:891-901,1990.
23. Diener HC, Dichgans J, Scholz E, et al: Analgesic-induced chronic headache: Long-term results of withdrawal therapy. J Neurol 236:914, 1989.
24. Kudrow L: Paradoxical effects of frequent analgesic use. Adv Neurol 33:335-341, 1982.
25. Saper JR: Ergotamine dependency-a review. Headache 27:435-438, 1987.
26. Göbel H, Stolze H, Heinze A, et al: Easy therapeutical management of sumatriptan-induced daily headache. Neurology 47:297-298,1996.
27. Evers S, Gralow I, Bauer B, et al: Sumatriptan and ergotamine overuse and drug-induced headache: A clinicoepidemiologic study. Clin Neuropharmacol 22:201-206, 1999.
28. Tfelt-Hansen P: How to define the best efficacy parameters for migraine. Cephalalgia 17(suppl 17):6-8; discussion 8-9,1997.
29. Imitrex (sumatriptan succinate) tablets. Package insert. Research Triangle Park, NC, Glaxo Wellcome, Inc, Feb 1998.
30. Amerge (naratriptan hydrochloride). Package insert. Research Triangle Park, NC, Glaxo Wellcome, Inc, Feb 1998.
31. Zomig (zolmi trip tan). Package insert. Wilmington, DE, Zeneca Pharmaceutical, Nov 1997.
32. Maxalt (rizatriptan benzoate) tablets and Maxalt-MLT (rizatriptan benzoate) orally disintegrating tablets. Package insert. West Point, PA, Merck and Co, Inc, Oct 1998.
33. Plosker GL, McTavish D: Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drags 47:622-651, 1994.
34. Perry CM, Markham A: Sumatriptan. An updated review of its use in migraine. Drags 55:889-922, 1998.
35. Spencer CM, Gunasekara NS, Hills C: Zolmitriptan: A review of its use in migraine. Drags 58:347-374, 1999.
36. Dulli DA: Naratriptan: An alternative for migraine. Ann Pharmacother 33:704-711, 1999.
37. Martin GR: Serotonin receptor involvement in the pathogenesis and treatment of migraine, in Goadsby PJ, Silberstein SB (eds): Headache. Blue Books of Practical Medicine, vol 17. Newton, MA, ButterworthHeinemann, 1997, pp 25-38.
38. Longmore J, Shaw D, Smith D, et al: Differential distribution of 5HT1D- and SHTlB-immunoreactivity within the human trigeminocerebrovascular system: Implications for the discovery of new antimigraine drugs. Cephalalgia 17:833-842, 1997.
39. Connor H, Beattie D: 5-Hydroxytryptamine receptor subtypes: Relation to migraine, in Edvinsson L (ed): Migraine & Headache Pathophysiology. London, Martin Dunitz Ltd, 1999, pp 43-52.
40. Pauwels PJ, John GW: Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol 22:123-136, 1999.
41. Humphrey PP, Feniuk W, Perren MJ, et al: The pharmacology of the novel 5-HTl-like receptor agonist, GR43175. Cephalalgia 9 (suppl 9J-.23-33, 1989.
42. Humphrey PP, Feniuk W: Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sei 12:444-446, 1991.
43. Humphrey PP, Goadsby PJ: The mode of action of sumatriptan is vascular? A debate. Cephalalgia 14:401-410; discussion 393,1994.
44. Saxena PR, De Vries P, Wang W, et al: Effects of avitriptan, a new 5HT IB/ID receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmacol 355:295-302, 1997.
45. de Vries P, Willems EW, Heilgers JPC, et al: Constriction of porcine carotid arteriovenous anastomoses as indicator of antimigraine activity: The role of 5-HTlB/lD receptors as well as unidentified receptors, in Edvinsson L, (ed): Migraine & Headache Pathophysiology. London, Martin Dunitz Ltd, 1999, pp 119-32.
46. Moskowitz MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sei 13:307311, 1992.
47. Moskowitz MA: Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43:S16-S20, 1993.
48. Hoskin KL, Kaube H, Goadsby PJ: Sumatriptan can inhibit trigeminal afférents by an exclusively neural mechanism. Brain 119:1419-1428, 1996.
49. Goadsby PJ, Knight YE: Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat. Cephalalgia 17:153-158, 1997.
50. Goadsby PJ, Knight Y: Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxytryptamine (5-HT[lB/lD]) receptors. BrJ Pharmacol 122:918-922,1997.
51. Goadsby PJ, Edvinsson L: Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (SHT)-lD receptor agonist 311C90. Headache 34:394-399, 1994.
52. Goadsby PJ, Hoskin KL: Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HTJ1B/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine? Pain 67:355-359, 1996.
53. Cumberbatch MJ, Hill RG, Hargreaves RJ: Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 328:37-40, 1997.
54. Cumberbatch MJ, Hill RG, Hargreaves RJ: The effects of 5-HT1A, 5HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Eur J Pharmacol 362:43-46, 1998.
55. Cumberbatch MJ, Hill RG, Hargreaves RJ: Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 18:659-663,1998.
56. Lacey LF, Hussey EK, Fowler PA: Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47:543-548, 1995.
57. Fowler PA, Lacey LF, Thomas M, et al: The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. EurNeurol 31:291294, 1991.
58. Warner PE, Brouwer KL, Hussey EK, et al: Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm Res 12:138-143, 1995.
59. Duquesnoy C, Mamet JP, Sumner D, et al. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. EUT ] Pharm Sei 6:99-104, 1998.
60. Moore KH, Hussey EK, Shaw S, et al: Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 17:541-550, 1997.
61. Williams P, Fuseau E, Cosson V, et al: Sumatriptan pharmacokinetics are significantly altered by monoamine oxidase inhibitor co-administration (abstract). Cephalalgia 17:408, 1997.
62. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group. EUT Neural 31:323-331, 1991.
63. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med 325:316-321, 1991.
64. Ensink FB: Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group. J Neural 238 (suppl 1):S66-S69, 1991.
65. Dahlöf C, Edwards C, Toth A: Sumatriptan injection is superior to placebo in the acute treatment of migraine-with regard to both efficacy and general well-being. Cephalalgia 12:214-220,1992.
66. Mathew NT, Dexter J, Couch J, et al: Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neural 49:1271-1276, 1992.
67. Bousser MG, D'Allens H, Richard A: Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: A placebocontrolled trial. Early-Morning Migraine Sumatriptan Study Group. fintern Med 234:211-216, 1993.
68. Cady RK, Wendt JK, Kirchner JR, et al: Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265:2831-2835, 1991.
69. Cady RK, Dexter J, Sargent JD, et al: Efficacy of subcutaneous sumatriptan in repeated episodes of migraine (published erratum appears in Neurology 43(10):2010, 1993).
70. Neurology 43:1363-1368, 1993.
71. Gross ML, Kay J, Turner AM, et al: Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group. Headache 34:559-563, 1994.
72. Russell MB, Holm-Thomsen OE, Rish0j Nielsen M, et al: A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia 14:291-296, 1994.
73. Mushet GR, Cady RK, Baker CC, et al: Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Clin Ther 18:687-699, 1996.
74. Jensen K, Tfelt-Hansen P, Hansen EW, et al: Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Cephalalgia 15:423-429, 1995.
75. Brown EG, Endersby CA, Smith RN, et al: The safety and tolerability of sumatriptan: An overview. Eur Neural 31:339-344, 1991.
76. Salonen R, Ashford E, Dahlöf C, et al: Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neural 241:463-469, 1994.
77. Ryan R, Elkind A, Baker CC, et al: Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 49:1225-1230, 1997.
78. Diamond S, Elkind A, Jackson RT, et al: Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 7:234-240, 1998.
79. Sargent J, Kirchner JR, Davis R, et al: Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multi- i center study. Neurology 45 (suppl 7):S10-S14,1995.
80. Pfaffenrath V, Cunin G, Sjonell G, et al: Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 38:184-190, 1998.
81. Cutler N, Mushet GR, Davis R, et al: Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Afeuro7ogy45(suppl 7):S5-S9, 1995.
82. Cull RE, Price WH, Dunbar A: The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. J Neurol Neurosurg Psychiatry 62:490-495, 1997.
83. Tfelt-Hansen P: Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 18:532-538,1998.
84. Visser WH, Jaspers NM, de Vriend RH, et al: Chest symptoms after sumatriptan: A two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 16:554-559,1996.
85. Houghton LA, Foster JM, Whorwell PJ, et al: Is chest pain after sumatriptan oesophageal in origin? Lancet 344:985-986, 1994.
86. Ottervanger JP, Valkenburg HA, Grobbee DE, et al: Characteristics and determinants of sumatriptan-associated chest pain. Arch Neurol 54:1387-1392, 1997.
87. MaassenVanDenBrink A, Reekers M, Bax WA, et al: Coronary sideeffect potential of current and prospective antimigraine drugs. Circulation 98:25-30, 1998.
88. Maclntyre PD, Bhargava B, Hogg KJ, et al. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87:401-405,1993.
89. Mueller L, Gallagher RM, Ciervo CA: Vasospasm-induced myocardial infarction with sumatriptan. Headache 36:329-331,1996.
90. O'Connor P, Gladstone P: Oral sumatriptan-associated transmural myocardial infarction. Neurology 45:2274-2276, 1995.
91. Kelly KM: Cardiac arrest following use of sumatriptan. Neurology 45:1211-1213, 1995.
92. Ottervanger JP, Paalman HJ, Boxma GL, et al: Transmural myocardial infarction with sumatriptan. Lancet 341:861-862, 1993.
93. Walton-Shirley M, Flowers K, Whiteside JH: Unstable angina pectoris associated with Imitrex therapy [letter]. Cathet Cardiovasc Diagn 34:188, 1995.
94. Knudsen JF, Friedman B, Chen M, et al: Ischémie colitis and sumatriptan use. Arch Intern Med 158:1946-1948, 1998.
95. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The multinational oral sumatriptan and cafergot comparative study group. EUT Neural 31:314-322, 1991.
96. Raskin NH: Headache, ed 2. New York, Churchill Livingstone, 1988.
97. Dixon R, Warrander A: The clinical pharmacokinetics of zolmitriptan. Cephalalgia 17 (suppl 18):15-20,1997.
98. Wild MJ, Butters CJ, McKillop D: Determination of the human hepatic cytochrome P450 isozymes involved in zohnitriptan and Ndesmethyl zolmitriptan metabolism in vitro (abstract). Br J Clin Pharm 46:290P, 1998.
99. Dixon R, French S, Kemp J, et al: Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. J Clin Pharmacol 38:694-701,1998.
100. Visser WH, Klein KB, Cox RC, et al: 311C90, A new central and peripherally acting 5-HTlD receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, dose-range finding study. Neurology 46:522-526, 1996.
101. Rapoport AM, Ramadan NM, Adelman JU, et al: Optimizing the dose of zolmitriptan (Zornig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 49:1210-1218, 1997.
102. Solomon GD, Cady RK, Klapper JA, et al: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology 49:1219-1225, 1997.
103. Dahlöf C, Diener HC, Goadsby PJ, et al: Zolmitriptan, a 5HT1B/1D receptor agonist for the acute oral treatment of migraine: A multicentre, dose-range finding study. EUT]Neural 5:535-543, 1998.
104. Edmeads JG, Millson DS: Tolerability profile of zolmitriptan (Zornig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan. Cephalalgia 17 (suppl 18):41-52, 1997.
105. Sciberras DG, Polvino WJ, Gertz BJ, et al: Initial human experience with MK-462 (rizatriptan): A novel 5-HTlD agonist (published erratum appears in Br J Clin Pharmacol 43(4):450, 1997).
106. Br J Clin Pharmacol 43:49-54, 1997.
107. Cheng H, Polvino WJ, Sciberras D, et al: Pharmacokinetics and food interaction of MK-462 in healthy males. Biopharm DrugDispos 17:1724, 1996.
108. Lipton RB: Pharmacological profile and clinical efficacy of rizatriptan. Headache 39 (suppl 1):S9-S15, 1999.
109. Goldstein J, Ryan R, Kaihong J, et al: Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache 38:737-747, 1998.
110. Teall J, Tuchman M, Cutler N, et al: Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 38:281-287, 1998.
111. Visser WH, Terwindt GM, Reines SA, et al: Rizatriptan vs. sumatriptan in the acute treatment of migraine. A placebo-controlled, doseranging study. Dutch/US Rizatriptan Study Group. Arch Neural 53:1132-1137, 1996.
112. Gijsman H, Kramer MS, Sargent J, et al: Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 17:647-651, 1997.
113. Kramer MS, Matzura-Wolfe D, Polis A, et al: A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 51:773781, 1998.
114. Tfelt-Hansen P, Teall J, Rodriguez F, et al: Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. Headache 38:748-755, 1998.
115. Block GA, Goldstein J, Polis A, et al. Efficacy and safety of rizatriptan versus standard care during long term treatment for migraine. Headache 38:764-771, 1988.
116. Ahrens SP, Farmer MV, Williams DL et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 19:525-30, 1999.
117. Fuseau E, Baille P, Kempsford RD: A study to determine the absolute bioavailability of naratriptan (abstract). Cephalalgia 17:418, 1997.
118. Kempsford RD, Baille P, Fuseau E: Oral naratriptan tablets (2.5-10 mg) exhibit dose proportional pharmacokinetics (abstract). Cephalalgia 17:409, 1997.
119. Fuseau E, Baille P, Kempsford RD: The pharmacokinetics of oral naratriptan in healthy subjects (abstract). J Neural Sei 150(suppl):Sl04, 1997.
120. Kempsford RD, Baille P, Snell P, et al: Oral naratriptan pharmacokinetics are predictable in subjects with impaired renal function (abstract). Cephalalgia 17:409-410, 1997.
121. Klassen A, Elkind A, Asgharnejad M, et al: Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. Headache 37:640-645, 1997.
122. Mathew NT, Asgharnejad M, Peykamian M, et al: Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 49:1485-1490, 1997.
123. Mathew NT, Asgharnejad M, Peykamian M, et al: Reply to "Naratriptan is effective and well tolerated in the acute treatment of migraine" (letter). Neurology 52:1300-1301, 1999.
124. Goadsby PJ: A triptan too far? (editorial). J Neural Neurosurg Psychiatry 64:143-147, 1998.
125. Cook RJ, Sackett DL: The number needed to treat: A clinically useful measure of treatment effect (published erratum appears in BMJ 22:310{6986):1056, 1995).
126. BMJ 310:452-454, 1995.
127. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318:1728-1733, 1988.
128. McQuay HJ, Moore RA: Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126:712-720, 1997.
129. Moore RA: New developments in evidence-based decision-making: Relevance of pain treatment and research, in Max M (ed): Pain 1999an updated review. Seattle, WA, IASP Press, 1999, pp 423-432.
130. Price DD, Fields HL: What are the causes of placebo analgesia? A behavioral-experimental analysis. Pain Forum 6:44-52, 1997.
131. Horton BT, Peters GA, Blumenthal LS: A new product in the treatment of migraine: A preliminary report. Mayo Clinic Proc 20:241-248, 1945.
132. Raskin NH: Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 36:995-997, 1986.
133. Winner P, Ricalde O, Le Force B, et al: A double-blind study of subcutaneous dihydroergotamine vs. subcutaneous sumatriptan in the treatment of acute migraine. Arch Neural 53:180-184,1996.
134. Touchon J, Bertin L, Pilgrim AJ, et al: A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 47:361-365,1996.
135. Gallagher RM: Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neural 53:1285-1291, 1996.
136. de Metz JE, van Zwieten PA: Differential effects of dihydroergotamine on the circulatory actions of arterial and venous dilators in the rat. J Cardiovasc Pharmacol 3:217-227, 1981.
137. McCarthy BG, Peroutka SJ: Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175). Headache 29:420-422, 1989.
138. Hoyer D, Schoeffter P, Gray JA: A comparison of the interactions of dihydroergotamine, ergotamine, and GR 43175 with 5HT1 receptor. Cephalalgia 9:3401, 1989.
139. Kanto J, Allonen H, Koski K, et al: Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. Int J Clin Pharmacol Ther Toxicol 19:127-130, 1981.
140. Migranol (dihydroergotamine mesylate) nasal spray. Package insert. Novartis Pharmaceuticals, Dec 1997.
141. van den Berg E, Walterbusch G, Götzen L, et al: Ergotism leading to threatened limb amputation or to death in two patients given heparin-dihydroergotamine prophylaxis (letter). Lancet 1:955-956, 1982.
142. Scherf D, Schalman M: Electrocardiographic and clinical studies on the action of ergotamine tartrate and dihydroergotamine 45. Am J Med Sei 216:673-679, 1948.
143. Bousser MG, Loria Y: Efficacy of dihydroergotamine nasal spray for the treatment of migraine attacks: A comparative double blind crossover study with placebo. Cephalalgia 5:554-555,1985.
144. Krause KH, Bleicher MA: Dihydroergotamine nasal spray in the treatment of migraine attacks (abstract). Cephalalgia 5:138-139,1985.
145. Massiou H: Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: Two controlled trials versus placebo (abstract). Cephalalgia 7:440-441, 1987.
146. Tulunay FC, Karan O, Aydin N, et al: Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo. Cephalalgia 7:131-133,1987.
147. Ziegler D, Ford R, Kriegler J, et al: Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 44:447-453,1994.
148. Lipton RB, Stewart WF, Ryan RE, Jr, et al: Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neural 55:210-217, 1998.
149. Bach FW: Opioids in headache, in Kalso E, McQuay HJ, WiesenfeldHallin Z (eds): Opioids Sensitivity of Chronic Noncancer Pain. Progress in pain research and management, vol 14. Seattle, WA, IASP Press, 1999, pp 367-370.
150. Ziegler DK. Opiate and opioid use in patients with refractory headache. Cephalalgia 14:5-10,1994.
151. Markley HG: Chronic headache: Appropriate use of opiate analgesics. Neurology 44:S18-S24, 1994.
152. Koffert MJ, Couch JR, Diamond S, et al. Transnasal butorphanol in the treatment of acute migraine. Headache 35:65-69,1995.
153. Fisher MA, Glass S: Butorphanol (Stadol): A study in problems of current drug information and control. Neurology 48:1156-1160,1997.
154. Gillis JC, Benfield P, Goa KL: Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 50:157-175,1995.
155. Silberstein SD: Migraine and pregnancy. Neural Clin 15:209-231, 1997.
156. Volans GN: The effect of metoclopramide on the absorption of effervescent aspirin in migraine. ET J Clin Pharmacol 2:57-63,1975.
157. Volans GN. Migraine and drug absorption. Clin Pharmacokinet 3:313-318, 1978.
158. Boyle R, Behan PO, Sutton JA: A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. BrJ Clin Pharmacol 30:405-409,1990.
159. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. Eur Neural 32:177-184, 1992.
160. Tfelt-Hansen P, Henry P, Mulder LJ, et al: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346:923-926,1995.